Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tesamorelin 2 Milligrams · 1 trial · 1 indication
Pinch strength measure as measured by a pinch gauge.
| Arm | Type | Description |
|---|---|---|
| Tesamorelin treatment | EXPERIMENTAL | - |
| No Drug | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Tesamorelin 2 Milligrams (MG) | DRUG | Daily self-administered study drug |
Inclusion Criteria: * Ulnar nerve laceration at the wrist, repaired primarily Exclusion Criteria: * Certain cancers (active or in the past) * Uncontrolled diabetes or hypertension * Certain pituitary problems * Oral contraceptives * Pregnancy * Drug or alcohol dependence * Psychosocial issues tha...
Tesamorelin 2 Milligrams is an investigational small molecule being developed for the treatment of peripheral nerve injuries. It is currently in Phase 2 clinical development and has not been approved by the FDA. The drug is being studied to improve functional outcomes after peripheral nerve injury.
Tesamorelin 2 Milligrams is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with peripheral nerve injuries.
Tesamorelin 2 Milligrams is currently in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 2 trial is recruiting participants to assess the drug's ability to improve functional outcomes after peripheral nerve injury.
Tesamorelin 2 Milligrams is being evaluated in one active Phase 2 clinical trial with the identifier NCT03150511. This randomized, double-blind, no-treatment controlled trial is enrolling 36 participants aged 18 years and older in the United States to study the drug's effects on functional outcomes after peripheral nerve injury.
Yes, Tesamorelin 2 Milligrams is also known as Tesamorelin 2 Milligrams (MG). Both names refer to the same investigational drug being developed by United Therapeutics Corporation for the treatment of peripheral nerve injuries.